- Home
- MTNB
as 07-26-2024 4:00pm EST
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | BEDMINSTER |
| Market Cap: | 39.9M | IPO Year: | N/A |
| Target Price: | $3.00 | AVG Volume (30 days): | 872.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.12 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.11 - $0.89 | Next Earning Date: | 08-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Matinas Biopharma Holdings Inc. News
MTNB Breaking Stock News: Dive into MTNB Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program
GlobeNewswire
a month ago
Matinas BioPharma’s Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin
GuruFocus.com
a month ago
A Data-Driven Analysis of Netflix's Streaming Dominance and Future Outlook
Energy Global
a month ago
ANDRITZ to equip new Silvan hydropower plant in Türkiye
USA TODAY
a month ago
Supreme Court Justice Alito talks polarization, his wife talks revenge in secret recordings
Business Wire
a month ago
Pacer ETFs Rings in its 9th Anniversary as Firm nears $50 Billion in Assets Under Management
Business Wire
a month ago
Indra Energy Drives Sustainability Focus through the Penguins Pledge with the Pittsburgh Penguins
GlobeNewswire
a month ago
SEALSQ to Launch Two New Quantum Resistant Chips
Compare MTNB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MTNB Matinas Biopharma Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.